UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000000499
Receipt No. R000000604
Official scientific title of the study Randomized Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary
Date of disclosure of the study information 2006/10/10
Last modified on 2018/08/13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Randomized Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary
Title of the study (Brief title) Phase III Trial of (TC) Therapy versus (CPT-P) Therapy for Clear Cell Carcinoma of the Ovary
Region
Japan Asia(except Japan) Europe

Condition
Condition clear cell carcinoma of the ovary
Classification by specialty
Obsterics and gynecology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To compare the efficacy and safety of standard arm of paclitaxel plus carboplatin and experimental arm of irinotecan plus cisplatin in clear cell carcinoma of the ovary.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Phase III

Assessment
Primary outcomes Progression - Free Survival
Key secondary outcomes Overall Survival,Response Rate,Adverse Event

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification YES
Dynamic allocation YES
Institution consideration Institution is not considered as adjustment factor.
Blocking NO
Concealment Central registration

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Paclitaxel 175 mg/m2 day 1+ Carboplatin AUC 6 day 1 q 3 weeks 6 cycles
Interventions/Control_2 Irinotecan 60 mg/m2 day 1,8,15+ Cisplatin 60 mg/m2 day 1 q 4 weeks 6 cycles
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
18 years-old <=
Age-upper limit

Not applicable
Gender Female
Key inclusion criteria 1) Patients with a histological diagnosis of clear cell carcinoma of the ovary, FIGO Stages I to IV. All patients must have had appropriate surgery for ovarian carcinoma with appropriate tissue available for histological evaluation. In the case with concurrent presence of other histological cell types, clear cell histology must be dominant ( > 50%). The histological
diagnosis will be confirmed by a central pathology review (CPR) (Three pathology slides required.)
2) Age: 18 or older
3) ECOG Performance Status: 0 - 1
4) Reasonable organ function: Must be assessed within 14 days prior to randomization.
Absolute Neutrophil Count: 1,500 / mm3 or more
Platelet: 100,000 / mm3 or more
Renal Function: Serum creatinine should be 1.5 x institutional ULN or less. If patient has serum creatinine of 1 x ULN to 1.5 x ULN, she must have creatinine clearance > 60 ml/min
* Creatinine clearance should be calculated using the Modified Jelliffe formula
Hepatic Function: Bilirubin less than or equal to 1.5 x institutional ULN ( < CTCAE grade 1). AST (SGOT) and alkaline phosphatase less than or equal to 2.5 x institutional ULN ( < CTCAE grade 1).
Neurologic function: Neuropathy (sensory and motor) less than or equal to CTCAE grade 1.
5) Patient must have signed informed consent.
6) Patients must be enrolled within 6 weeks after comprehensive staging surgery.
Key exclusion criteria 1) Patients with a current diagnosis of epithelial ovarian tumor of low malignant potential
2) Patients with other malignancies including synchronous primary endometrial cancer or a past history of primary endometrial cancer
3) Patients who have received prior chemotherapy or radiation therapy to treat the current disease
4) Patients who received intraperitoneal chemotherapy at the time of operation
5) Patients with a prior diagnosis of malignancy are not eligible. Exceptions are:
- stage 0 endometrial cancer
- carcinoma in situ of the cervix
- non-melanoma skin cancer
- other malignancies curatively treated and > 5 years without evidence of recurrence
6) Patients who have received prior radiotherapy
Exceptions
Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than 5 years prior to registration, and the patient remains free of recurrent or metastatic disease.
7) Patients who have received prior chemotherapy.
Exceptions
Patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than 5 years prior to registration, and that the patient remains free of recurrent or metastatic disease.
8,9,10) Patients with diarrhea greater than CTCAE grade1, active infection that requires antibiotics, ongoing gastrointestinal bleeding requiring blood product support
11) Patients with unstable angina or those who have had a myocardial infarction within the past six months.
Patients with evidence of abnormal cardiac conduction are eligible if their disease has been stable for the past six months.
12,13,14,16) Patients with bowel obstruction, interstitial pneumonitis, massive pleural effusion and/or ascites, known hypersensitivity to polyoxyethylated castor oil or any of four chemotherapeutic agents
15,17,18) Patients who are under treatment with Atazanavir, pregnant or lactating, would not permit completion of study or required follow-up.

Target sample size 662

Research contact person
Name of lead principal investigator Toru Sugiyama ,M.D.,Ph.D.
Organization Iwate Medical University, School of Medicine
Division name Department of Obsterics and Gynecology
Address Uchimaru 19-1, Morioka, Iwate 020-8505 Japan
TEL 019-651-5111
Email jgog3017@insti.kitasato-u.ac.jp

Public contact
Name of contact person Toru Sugiyama ,M.D.,Ph.D.
Organization GCIG/JGOG3017 Office
Division name Iwate Medical University, School of Medicine, Department of Obsterics and Gynecology
Address Uchimaru 19-1, Morioka, Iwate 020-8505 Japan
TEL 019-651-5111
Homepage URL http://www.jgog.gr.jp/
Email jgog3017@insti.kitasato-u.ac.jp

Sponsor
Institute Japanese Gynecologic Oncology Group
Institute
Department

Funding Source
Organization Japanese Gynecologic Oncology Group
Organization
Division
Category of Funding Organization Non profit foundation
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2006 Year 10 Month 10 Day

Progress
Recruitment status Completed
Date of protocol fixation
2006 Year 09 Month 18 Day
Anticipated trial start date
2006 Year 10 Month 01 Day
Last follow-up date
2013 Year 03 Month 01 Day
Date of closure to data entry
2013 Year 06 Month 01 Day
Date trial data considered complete
2013 Year 06 Month 01 Day
Date analysis concluded
2013 Year 09 Month 01 Day

Related information
URL releasing protocol http://www.jgog.gr.jp/
Publication of results Published
URL releasing results https://www.ncbi.nlm.nih.gov/pubmed/27400948
Results - The results from the final analysis did not show a marked difference in both
PFS and OS between the patients who received the [standard treatment] and those whoreceived the [experimental treatment].
- The characteristics of side effect of these two treatments differ significantly.
Other related information

Management information
Registered date
2006 Year 10 Month 04 Day
Last modified on
2018 Year 08 Month 13 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000604

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.